advertisement

---

Razeghinejad R 10

Showing records 1 to 10 | Display all abstracts from Razeghinejad R

96467 Ocular manifestations of endocrine disorders
Nowroozzadeh MH
Clinical and Experimental Optometry 2021; 0: 1-12

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Shiuey EJ
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

96467 Ocular manifestations of endocrine disorders
Thornton S
Clinical and Experimental Optometry 2021; 0: 1-12

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Mehran NA
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

96467 Ocular manifestations of endocrine disorders
Watson A
Clinical and Experimental Optometry 2021; 0: 1-12

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Ustaoglu M
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

96467 Ocular manifestations of endocrine disorders
Syed ZA
Clinical and Experimental Optometry 2021; 0: 1-12

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Zhang Q
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---

96467 Ocular manifestations of endocrine disorders
Razeghinejad R
Clinical and Experimental Optometry 2021; 0: 1-12

---

95894 The effectiveness and safety profile of netarsudil 0.02% in glaucoma treatment: real-world 6-month outcomes
Razeghinejad R; Shukla AG; Shukla AG; Kolomeyer NN; Kolomeyer NN; Myers JS; Lee D
Graefe's Archive for Clinical and Experimental Ophthalmology 2022; 260: 967-974

---